Manhem P, Bramnert M, Hulthén U L, Hökfelt B
Eur J Clin Invest. 1981 Oct;11(5):389-95. doi: 10.1111/j.1365-2362.1981.tb02001.x.
The studies were designed to explore the effect of the converting enzyme inhibitor captopril on the activity of the sympathetic nervous system during basal conditions and following graded physical exercise in patients with essential hypertension. Seven males and two females, aged 36-59 years, were hospitalized under metabolic ward conditions and treated for 7 days with captopril given orally in increasing dosages, the final dose being 600 mg daily. The patients were subjected to an individual, graded submaximal work test (bicycling) for 20 min before medication and then again in an identical manner during medication with 600 mg captopril. Blood samples were drawn before exercise and then after 10 and 20 min of work for the determination of plasma angiotensin II (PA II), plasma aldosterone (PAC), plasma renin activity (PRA), plasma noradrenaline (PNA) and plasma adrenaline (PA). Before medication blood pressure (mmHg) was 195/133 immediately before exercise, 230/129 after 10 min of moderate exercise and 263/105 following 20 mon of nearly maximal work. During treatment with captopril the respective blood pressure values were 154/110, 200/100 and 245/98. Captopril had no significant effect on the changes in heart rate following physical exercise. PA II and PAC were substantially reduced and PRA considerably increased by captopril. PA II, PAC and PRA increased in response to exercise both before and following captopril. The exercise stimulated increase in PNA and PA was almost identical before and during captopril. Thus, captopril had no major effect on the activity of the sympathetic nervous system in patients with essential hypertension, neither during basic conditions nor during heavy physical exercise in spite of a profound decrease in PA II.
这些研究旨在探讨转化酶抑制剂卡托普利在基础状态下以及原发性高血压患者进行分级体育锻炼后对交感神经系统活性的影响。7名男性和2名女性,年龄在36 - 59岁之间,在代谢病房条件下住院,并接受卡托普利口服治疗7天,剂量逐渐增加,最终剂量为每日600毫克。患者在用药前进行了一项个体化的分级次极量运动试验(骑自行车)20分钟,然后在服用600毫克卡托普利期间以相同方式再次进行。在运动前以及运动10分钟和20分钟后采集血样,用于测定血浆血管紧张素II(PA II)、血浆醛固酮(PAC)、血浆肾素活性(PRA)、血浆去甲肾上腺素(PNA)和血浆肾上腺素(PA)。用药前,运动前血压(mmHg)为195/133,中度运动10分钟后为230/129,接近最大运动量20分钟后为263/105。在用卡托普利治疗期间,相应的血压值分别为154/110、200/100和245/98。卡托普利对体育锻炼后心率的变化没有显著影响。卡托普利使PA II和PAC大幅降低,PRA显著增加。在服用卡托普利前后,运动均使PA II、PAC和PRA增加。运动刺激引起的PNA和PA增加在服用卡托普利之前和期间几乎相同。因此,尽管PA II大幅下降,但卡托普利对原发性高血压患者交感神经系统的活性在基础状态下和剧烈体育锻炼期间均无重大影响。